Skip to Content
Merck
All Photos(4)

Key Documents

ABC225

Sigma-Aldrich

Anti-phospho USP7 (Ser18) Antibody

from rabbit, purified by affinity chromatography

Synonym(s):

Ubiquitin carboxyl-terminal hydrolase 7, Deubiquitinating enzyme 7, Herpesvirus-associated ubiquitin-specific protease, Ubiquitin thioesterase 7, Ubiquitin-specific-processing protease 7

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

rabbit

Quality Level

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

purified by

affinity chromatography

species reactivity

human

species reactivity (predicted by homology)

mouse (based on 100% sequence homology), rat (based on 100% sequence homology), porcine (based on 100% sequence homology), Xenopus (based on 100% sequence homology)

technique(s)

inhibition assay: suitable (peptide)
western blot: suitable

NCBI accession no.

UniProt accession no.

shipped in

wet ice

target post-translational modification

phosphorylation (pSer18)

Gene Information

human ... USP7(7874)

General description

Ubiquitin-specific-processing protease 7 (USP7) is also known as Ubiquitin carboxyl-terminal hydrolase 7 or Herpesvirus-associated ubiquitin-specific protease (HAUSP). USP7 is a ubiquitin specific protease or a deubiquitylating enzyme that cleaves ubiquitin from its substrates. Since ubiquitylation (polyubiquitination) is most commonly associated with the stability and degradation of cellular proteins, USP7 activity generally stabilizes its substrate proteins, and it is most popularly known as a direct antagonist of Mdm2, the E3 ubiquitin ligase for the tumor suppressor protein, p53.

Immunogen

Epitope: Near N-terminus
KLH-conjugated linear peptide corresponding to a region near the N-terminus of human USP7 phosphorylated at Ser18.

Application

Peptide Inhibition Analysis: 0.2 µg/mL from a representative lot was blocked by a phospho-peptide in HeLa cell lysate.

Western Blotting Analysis: 0.02 µg/mL from a representative lot detected phospho USP7 (Ser18) in HeLa cell lysate (Prof. Grigory Dianov, University of Oxford, U.K.).

Western Blotting Analysis: 0.02 µg/mL from a representative lot detected 100 ng of phospho USP7 (Ser18), and not dephosphorylated USP7 (Prof. Grigory Dianov, University of Oxford, U.K.).

Alexa Fluor is a registered trademark of Life Technologies.
Research Category
Apoptosis & Cancer
Research Sub Category
Apoptosis - Additional
This Anti-phospho USP7 (Ser18) antibody is validated for use in western blotting & peptide inhibition assay for the detection of phospho USP7 (Ser18).

Quality

Evaluated by Western Blotting in HeLa cell lysate.

Western Blotting Analysis: 0.2 µg/mL of this antibody detected phospho USP7 (Ser18) in 10 µg of HeLa cell lysate.

Target description

~140 kDa observed

Physical form

Affinity purified
Purified rabbit polyclonal in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Storage and Stability

Stable for 1 year at 2-8°C from date of receipt.

Legal Information

ALEXA FLUOR is a trademark of Life Technologies

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Giovanna Carrà et al.
Oncotarget, 8(22), 35508-35522 (2017-04-19)
Chronic Lymphocytic Leukemia (CLL) is a lymphoproliferative disorder with either indolent or aggressive clinical course. Current treatment regiments have significantly improved the overall outcomes even if higher risk subgroups - those harboring TP53 mutations or deletions of the short arm

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service